Vanucizumab ELISA Kit

SKU: **GXEL00140** | Assay: Quantitative ELISA (Colorimetric)

The Vanucizumab ELISA Kit (SKU: GXEL00140) is a high-sensitivity quantitative ELISA for the quantitative measurement of Vanucizumab in Plasma, Serum. The assay covers a detection range of 0.31-5 μg/mL with a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm.

Background: Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.

Specifications

Product Name	Vanucizumab ELISA Kit
SKU	GXEL00140
Accession	P15692 & O15123
Alternative Names	RG-7221, RG7221, RO5520985, 1448221-05-3
Assay Type	Quantitative
Detection Method	Colorimetric
Sensitivity	0.156 μg/ml
Detection Range	0.31-5 μg/mL
Recovery	80-120%
Sample Types	Plasma, Serum
Storage	2-8°C. See Storage & Stability.
Note	For Research Use Only. Not for diagnostic procedures.

Storage & Stability

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Store at 2-8°C on receipt; avoid repeated freeze-thaw cycles.

Assay Genie Ltd, 25 Windsor Place, Dublin 2, D02 VY42, Ireland | +353 1 563 9720 | www.assaygenie.com | techsupport@assaygenie.com
Datasheet: https://store-h68l9z2lnx.mybigcommerce.com/content/Technical%20Manuals/ELISA/GXEL/GXEL00140.pdf | Version 1.0, 09 July 2026